Brief: Esperion Therapeutics Q2 Basic EPS USD -0.33
12/08/2024 11:00
Aug 12 (Reuters) - Esperion Therapeutics Q2 net income USD -61.925 million. * Q2 operating income USD 2.579 million * Q2 operating expenses USD 71.255 million * Q2 product sales USD 28.302 million
Recent news on Esperion Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. RESEARCH ROUNDUP- Applied Materials, Axsome Therapeutics, Onsemi